RxDoctor Payments Data

Gregory Jacob, MD

Pulmonary Disease · Covington, LANPI 1629430269

Payments from drug & device makers

$8,651in general payments, 2019–2025

Across 74 payments — averaging $116.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • GSK$315
  • AstraZeneca$309
  • Sanofi$206
  • United Therapeutics Corporation$182
  • Boehringer Ingelheim$136
  • plus $358 from 12 others

What the payments were for

  • Travel & lodging$1,08313%
  • Food & beverage$1,52718%
  • Education$6,01269%
  • Gifts$300%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,651 in reported general payments places this provider in the 60th percentile of 189 pulmonary disease providers in Louisiana.

See all pulmonary disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$70,870
Medicare patients
291
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter317$232,510
Breztri AerosphereBudesonide/Glycopyr/Formoterol130$91,335
SymbicortBudesonide/Formoterol Fumarate127$37,242
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$24,371
Breo ElliptaFluticasone/Vilanterol46$21,655
Spiriva RespimatTiotropium Bromide30$20,662
Spiriva HandihalerTiotropium Bromide14$16,273
Advair HfaFluticasone Propion/Salmeterol33$13,965
Albuterol Sulfate HfaAlbuterol Sulfate471$13,830
DuleraMometasone/Formoterol26$8,850
Combivent RespimatIpratropium/Albuterol Sulfate13$6,168
Varenicline Tartrate21$4,918
Fluticasone-SalmeterolFluticasone Propion/Salmeterol37$4,333
Azelastine Hcl128$3,124
Ventolin HfaAlbuterol Sulfate46$2,770

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$315$254,165363 claims
AstraZenecaBreztri Aerosphere, Symbicort$309$128,577257 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat$136$51,20181 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 189 pulmonary disease providers in Louisiana.

Other pulmonary disease in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →